-

Company Profile for Reven, LLC

--(BUSINESS WIRE)--Reven Holdings, Inc., a Delaware corporation, through its Golden, Colorado, based operating company Reven, LLC, is a biopharmaceutical company. Reven’s vision is to make a difference in the world by making its products accessible to everyone suffering the effects of vascular and metabolic related diseases. Reven is committed to being the premier, research-intensive biopharmaceutical company that advances the health and well-being of people around the world. Its primary product, Rejuveinix (RJX), targets patients suffering from COVID-19, sepsis, vascular and metabolic related diseases as well as specific patient populations suffering PAD and other cardiovascular related medical conditions.

Company:

Reven, LLC

 

 

Headquarters Address:

600 Corporate Circle

 

Suite D

 

Golden, CO 80401

 

 

Main Telephone:

(425) 305-9547

 

 

Website:

https://www.reven.com

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

CEO: Peter Lange

 

COO: Brian Denomme

 

CFO: Jeff Halverson

 

 

Investor Relations

 

Contact:

Jennifer Van Tuinen

Phone:

(720) 618-0658

Email:

jenny.vantuinen@reven.com

 

 

Public Relations

 

Contact:

Vincent Vanderbent

Phone:

(425) 305-9547

Email:

vincent.vanderbent@reven.com

 

Reven Holdings, Inc.


Release Versions

Social Media Profiles
More News From Reven Holdings, Inc.

Reven Holdings Announces the Publication of a Peer-reviewed Article in the Prestigious Medical Journal Frontiers in Oncology

WESTMINSTER, Colo.--(BUSINESS WIRE)--Exciting Medical and Scientific Progress Reported for Reven Holdings’ COVID-19 Drug Candidate...

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

WESTMINSTER, Colo.--(BUSINESS WIRE)--REVEN SUCCESSFULLY COMPLETES PART 1 OF THE RANDOMIZED COVID-19 STUDY EVALUATING ITS LEAD ANTI-SEPSIS DRUG CANDIDATE RJX...
Back to Newsroom